cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Annovis Bio
8 own
4 watching
Current Price
$11.49
$1.43
(14.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
100.16M
52-Week High
52-Week High
22.49000
52-Week Low
52-Week Low
5.42000
Average Volume
Average Volume
0.32M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization100.16M
icon52-Week High22.49000
icon52-Week Low5.42000
iconAverage Volume0.32M
iconDividend Yield--
iconP/E Ratio--
What does the Annovis Bio do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company s lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Read More
How much money does Annovis Bio make?
News & Events about Annovis Bio.
Business Wire
10 months ago
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinsons Disease (PD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback...
TipRanks Financial Blog
1 year ago
Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Research Report) yesterday and set a price target of $26.00. The ... Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS Res...
PR Newswire
1 year ago
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION PR Newswire BERWYN, Pa., April 11, 2023 BERWYN, Pa., April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis' or the...
PR Newswire
1 year ago
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease PR...
Frequently Asked Questions
Frequently Asked Questions
What is Annovis Bio share price today?
plus_minus_icon
Can Indians buy Annovis Bio shares?
plus_minus_icon
How can I buy Annovis Bio shares from India?
plus_minus_icon
Can Fractional shares of Annovis Bio be purchased?
plus_minus_icon
What are the documents required to start investing in Annovis Bio stocks?
plus_minus_icon
What is today’s traded volume of Annovis Bio?
plus_minus_icon
What is today’s market capitalisation of Annovis Bio?
plus_minus_icon
What is the 52-Week High and Low Range of Annovis Bio?
plus_minus_icon
What percentage is Annovis Bio down from its 52-Week High?
plus_minus_icon
What percentage is Annovis Bio up from its 52-Week Low?
plus_minus_icon
Current Price
$11.49
$1.43
(14.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00